Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: Increased transporter affinity and metabolic stability

Molecular Pharmaceutics

Volumn 5, Issue 5, 2008, Pages 717-727

  Tsume, Yasuhiro ^a   Hilfinger, John M ^b   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b TSRL INC   (United States)

Author keywords

Caco 2 and Capan 2 permeability; Dipeptide monoester floxuridine prodrugs; Metabolism; PEPT1; Thymidine phosphorylase

Indexed keywords

5' LEVO GLYCYL LEVO LEUCYLFLOXURIDINE; 5' LEVO GLYCYLFLOXURIDINE; 5' LEVO ISOLEUCYL LEVO GLYCYLFLOXURIDINE; 5' LEVO ISOLEUCYLFLOXURIDINE; 5' LEVO LEUCYL LEVO GLYCYLFLOXURIDINE; 5' LEVO LEUCYLFLOXURIDINE; 5' LEVO PHENYLALANYL LEVO GLYCYLFLOXURIDINE; 5' LEVO PHENYLALANYL LEVO TYROSYLFLOXURIDINE; 5' LEVO PHENYLALANYLFLOXURIDINE; 5' LEVO VALYL LEVO PHENYLALANYLFLOXURIDINE; 5' LEVO VALYLFLOXURIDINE; DIPEPTIDE; FLOXURIDINE; FLOXURIDINE DERIVATIVE; PEPTIDE TRANSPORTER 1; PRODRUG; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN CACO 2; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MONOLAYER CULTURE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; FLOXURIDINE; HUMANS; MOLECULAR STRUCTURE; PANCREATIC NEOPLASMS; PRODRUGS; THYMIDINE PHOSPHORYLASE;

EID: 56049109562     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800008c     Document Type: Article

References (49)

1. Han, H. K.; Oh, D. M.; Amidon, G. L. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm. Res. 1998, 15 (9), 1382-6.
2. Song, X.; Vig, B. S.; Lorenzi, P. L.; Drach, J. C.; Townsend, L. B.; Amidon, G. L. Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter. J. Med. Chem. 2005, 48 (4), 1274-7.
3. Song, X.; Lorenzi, P. L.; Landowski, C. P.; Vig, B. S.; Hilfinger, J. M.; Amidon, G. L. Amino acid ester prodrugs of the anticancer agent gemcitabine: Synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol. Pharmaceutics 2005, 2 (2), 157-67.
4. Friedrichsen, G. M.; Chen, W.; Begtrup, M.; Lee, C. P.; Smith, P. L.; Borchardt, R. T. Synthesis of analogs of L-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells. Eur. J. Pharm. Sci. 2002, 16 (1-2), 1-13.
5. Guo, A.; Hu, P.; Balimane, P. V.; Leibach, F. H.; Sinko, P. J. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J. Pharmacol. Exp. Ther. 1999, 289 (1), 448-54.
6. Anand, B. S.; Patel, J.; Mitra, A. K. Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: Competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2. J. Pharmacol. Exp. Ther. 2003, 304 (2), 781-91.
7. Landowski, C. P.; Sun, D.; Foster, D. R.; Menon, S. S.; Barnett, J. L.; Welage, L. S.; Ramachandran, C.; Amidon, G. L. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J. Pharmacol. Exp. Ther. 2003, 306 (2), 778-86.
8. Umapathy, N. S.; Ganapathy, V.; Ganapathy, M. E. Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm. Res. 2004, 21 (7), 1303-10.
9. Phan, D. D.; Chin-Hong, P.; Lin, E. T.; Anderle, P.; Sadee, W.; Guglielmo, B. J. Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor. Antimicrob. Agents Chemother. 2003, 47 (7), 2351-3.
10. Nishizawa, Y.; Casida, J. E. 3′, 5′ -diesters of 5-fluoro-2′-deoxyuridine: Synthesis and biological activity. Biochem. Pharmacol. 1965, 14 (11), 1605-19.
11. Vig, B. S.; Lorenzi, P. J.; Mittal, S.; Landowski, C. P.; Shin, H. C.; Mosberg, H. I.; Hilfinger, J. M.; Amidon, G. L. Amino acid ester prodrugs of floxuridine: Synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm. Res. 2003, 20 (9), 1381-8.
12. Kawaguchi, T.; Saito, M.; Suzuki, Y.; Nambu, N.; Nagai, T. Specificity of esterases and structure of prodrug esters. II Hydrolytic regeneration behavior of 5-fluoro-2′-deoxyuridine (FUdR) from 3′, 5′ -diesters of FUdR with rat tissue homogenates and plasma in relation to their antitumor activity. Chem. Pharm. Bull. (Tokyo) 1985, 33 (4), 1652-9.
13. Landowski, C. P.; Song, X.; Lorenzi, P. L.; Hilfinger, J. M.; Amidon, G. L. Floxuridine amino acid ester prodrugs: Enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm. Res. 2005, 22 (9), 1510-8.
14. Landowski, C. P.; Vig, B. S.; Song, X.; Amidon, G. L. Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol. Cancer Ther. 2005, 4 (4), 659-67.
15. Han, H.; de Vrueh, R. L.; Rhie, J. K.; Covitz, K. M.; Smith, P. L.; Lee, C. P.; Oh, D. M.; Sadee, W.; Amidon, G. L. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 1998, 15 (8), 1154-9.
16. Rubio-Aliaga, I.; Daniel, H. Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol. Sci. 2002, 23 (9), 434-40.
17. Anand, B. S.; Katragadda, S.; Mitra, A. K. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. J. Pharmacol. Exp. Ther. 2004, 311 (2), 659-67.
18. Meredith, D.; Temple, C. S.; Guha, N.; Sword, C. J.; Boyd, C. A.; Collier, I. D.; Morgan, K. M.; Bailey, P. D. Modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1. Eur. J. Biochem. 2000, 267 (12), 3723-8.
19. Surendran, N.; Covitz, K. M.; Han, H.; Sadee, W.; Oh, D. M.; Amidon, G. L.; Williamson, R. M.; Bigge, C. F.; Stewart, B. H. Evidence for overlapping substrate specificity between large neutral amino acid (LNAA) and dipeptide (hPEPT1) transporters for PD 158473, an NMDA antagonist. Pharm. Res. 1999, 16 (3), 391-5.
20. 6Wenzel, U.; Gebert, I.; Weintraut, H.; Weber, W. M.; Clauss, W.; Daniel, H. Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells. J. Pharmacol. Exp. Ther. 1996, 277 (2), 831-9.
21. Wenzel, U.; Thwaites, D. T.; Daniel, H. Stereoselective uptake of beta-lactam antibiotics by the intestinal peptide transporter. Br. J. Pharmacol. 1995, 116 (7), 3021-7.
22. Nielsen, C. U.; Andersen, R.; Brodin, B.; Frokjaer, S.; Taub, M. E.; Steffansen, B. Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line. J. Controlled Release 2001, 76 (1-2), 129-38.
23. Satake, M.; Enjoh, M.; Nakamura, Y.; Takano, T.; Kawamura, Y.; Arai, S.; Shimizu, M. Transepithelial transport of the bioactive tripeptide, Val-Pro-Pro, in human intestinal Caco-2 cell mono-layers. Biosci. Biotechnol. Biochem. 2002, 66 (2), 378-84.
24. Weller, S.; Blum, M. R.; Doucette, M.; Burnette, T.; Cederberg, D. M.; de Miranda, P.; Smiley, M. L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 1993, 54 (6), 595-605.
25. Gonzalez, D. E.; Covitz, K. M.; Sadee, W.; Mrsny, R. J. An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res. 1998, 58 (3), 519-25.
26. Kim, I.; Chu, X. Y.; Kim, S.; Provoda, C. J.; Lee, K. D.; Amidon, G. L. Identification of a human valacyclovirase: Biphenyl hydrolase-like protein as valacyclovir hydrolase. J. Biol. Chem. 2003, 278 (28), 25348-56.
27. Kim, I.; Song, X.; Vig, B. S.; Mittal, S.; Shin, H. C.; Lorenzi, P. J.; Amidon, G. L. A novel nucleoside prodrug-activating enzyme: Substrate specificity of biphenyl hydrolase-like protein. Mol. Pharmaceutics 2004, 1 (2), 117-27.
28. Laskin, J. D.; Evans, R. M.; Slocum, H. K.; Burke, D.; Hakala, M. T. Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res. 1979, 39 (2 Pt 1), 383-90.
29. Yamada, M.; Nakagawa, H.; Fukushima, M.; Shimizu, K.; Hayakawa, T.; Ikenaka, K. In vitro study on intrathecal use of 5-fluoro-2′-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors. J. Neurooncol. 1998, 37 (2), 115-21.
30. Grem, J. L. 5-Fluorouracil: Forty-plus and still ticking. A review of its preclinical and clinical development. Invest. New Drugs 2000, 18 (4), 299-313.
31. Parker, W. B.; Cheng, Y. C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Ther. 1990, 48 (3), 381-95.
32. van Laar, J. A.; Rustum, Y. M.; Ackland, S. P.; van Groeningen, C. J.; Peters, G. J. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur. J. Cancer 1998, 34 (3), 296-306.
33. Willmore, E.; Durkacz, B. W. Cytotoxic mechanisms of 5-fluoropyrimidines. Relationships with poly(ADP-ribose) polymerase activity, DNA strand breakage and incorporation into nucleic acids. Biochem. Pharmacol. 1993, 46 (2), 205-11.
34. Birnie, G. D.; Kroeger, H.; Heidelberger, C. Studies Of Fluorinated Pyrimidines. Xviii. The Degradation Of 5-Fluoro-2′-Deoxyuridine And Related Compounds By Nucleoside Phosphorylase. Biochemistry 1963, 2, 566-72.
35. Vabeno, J.; Lejon, T.; Nielsen, C. U.; Steffansen, B.; Chen, W.; Ouyang, H.; Borchardt, R. T.; Luthman, K. Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: Synthesis and biological investigations. J. Med. Chem. 2004, 47 (4), 1060-9.
36. Doring, F.; Will, J.; Amasheh, S.; Clauss, W.; Ahlbrecht, H.; Daniel, H. Minimal molecular determinants of substrates for recognition by the intestinal peptide transporter. J. Biol. Chem. 1998, 273 (36), 23211-8.
37. Terada, T.; Sawada, K.; Saito, H.; Hashimoto, Y.; Inui, K. Functional characteristics of basolateral peptide transporter in the human intestinal cell line Caco-2. Am. J. Physiol. 1999, 276 (6 Pt 1), G1435-41.
38. Anand, B. S.; Dey, S.; Mitra, A. K. Current prodrug strategies via membrane transporters/receptors. Expert Opin. Biol. Ther. 2002, 2(6), 607-20.
39. Steingrimsdottir, H.; Gruber, A.; Palm, C.; Grimfors, G.; Kalin, M.; Eksborg, S. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Antimicrob. Agents Chemother. 2000, 44 (1), 207-9.
40. Ganapathy, M. E.; Huang, W.; Wang, H.; Ganapathy, V.; Leibach, F. H. Valacyclovir: A substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun. 1998, 246 (2), 470-5.
41. Eriksson, A. H.; Elm, P. L.; Begtrup, M.; Nielsen, R.; Steffansen, B.; Brodin, B. hPEPT1 affinity and translocation of selected Gln-Sar and Glu-Sar dipeptide derivatives. Mol. Pharmaceutics 2005, 2 (3), 242-9.
42. Li, J.; Tamura, K.; Lee, C. P.; Smith, P. L.; Borchardt, R. T. Hidalgo, I. J. Structure-affinity relationships of Val-Val and Val-Val-Val stereoisomers with the apical oligopeptide transporter in human intestinal Caco-2 cells. J. Drug Targeting 1998, 5(5), 317-27.
43. Tamura, K.; Bhatnagar, P. K.; Takata, J. S.; Lee, C. P.; Smith, P. L.; Borchardt, R. T. Metabolism, uptake, and transepithelial transport of the diastereomers of Val-Val in the human intestinal cell line, Caco-2. Pharm. Res. 1996, 13 (8), 1213-8.
44. Lorenzi, P. L.; Landowski, C. P.; Song, X.; Borysko, K. Z.; Breitenbach, J. M.; Kim, J. S.; Hilfinger, J. M.; Townsend, L. B.; Drach, J. C.; Amidon, G. L. Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzinlidazole enhance metabolic stability in vitro and in vivo. J. Pharmacol Exp. Ther. 2005, 314 (2), 883-90.
45. Larsen, S. W.; Ankersen, M.; Larsen, C. Kinetics of degradation and oil solubility of ester prodrugs of a model dipeptide (GlyPhe). Eur. J. Pharm. Sci. 2004, 22 (5), 399-408.
46. Goolcharran, C.; Borchardt, R. T. Kinetics of diketopiperazine formation using model peptides. J. Pharm. Sci. 1998, 87(3), 283-8.
47. Jensen, E.; Bundgaard, H. Peptide esters as water-soluble prodrugs for hydroxyl containing agents: Chemical stability and enzymatic hydrolysis of benzyl esters of glycine, diglycine and triglycine. Int. J. Pharm. 1991, 71, 117-125.
48. Beauchamp, L. M.; Orr, G. F.; de Miranda, P.; Burnette, T.; Kernitsy, T. A. Amino acid ester prodrugs of acyclovir. Antiviral Chem. Chemother. 1992, 3, 157-164.
49. Woodman, P. W.; Sarrif, A. M.; Heidelberger, C. Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2′-deoxyuridine. Cancer Res. 1980, 40 (3), 507-11.